Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 5/20 | 0.48 |
| ▸ | RAB9A | P51151 | 6/20 | 0.46 |
| ▸ | NPC1 | O15118 | 5/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | LIPE | Q05469 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | GRM3 | Q14832 | 3/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.43 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.43 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1183595 | 1.00 | EPHX2 (0.48) | EPHX2RAB9ANPC1SMN1; SMN2POLB | |
| SCHEMBL1777738 | 1.00 | EPHX2 (0.48) | EPHX2RAB9ANPC1SMN1; SMN2POLB | |
| SCHEMBL2772712 | 0.88 | TACR3 (0.40) | EPHX2RAB9ANPC1SMN1; SMN2POLB | |
| SCHEMBL1698890 | 0.88 | TACR3 (0.40) | EPHX2RAB9ANPC1SMN1; SMN2POLB | |
| SCHEMBL3430000 | 0.88 | TACR3 (0.40) | EPHX2RAB9ANPC1SMN1; SMN2POLB | |
| SCHEMBL27924792 | 0.86 | LIPE (0.52) | EPHX2RAB9ANPC1SMN1; SMN2POLB | |
| SCHEMBL1710707 | 0.85 | AKR1C3 (0.48) | EPHX2RAB9ANPC1SMN1; SMN2POLB | |
| SCHEMBL21193698 | 0.85 | LIPE (0.37) | EPHX2RAB9ANPC1SMN1; SMN2POLB | |
| SCHEMBL20590848 | 0.85 | AKR1C3 (0.48) | EPHX2RAB9ANPC1SMN1; SMN2POLB | |
| SCHEMBL4516909 | 0.85 | AKR1C3 (0.48) | EPHX2RAB9ANPC1SMN1; SMN2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 140 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240238423-A9 | TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-XL DEGRADERS | Treeline Biosciences, Inc. | 2024-07-18 | — | — | US | disclosed |
| CN-112218863-B | O-glycoprotein-2-acetamido-2-deoxy-3-D-pyranoside enzyme inhibitors | 比奥根MA公司 | 2024-07-12 | — | — | CN | disclosed |
| US-20240217961-A1 | (S)-Mepazine Salt Forms, Process of Preparing, and Formulations Thereof | SHANGHAI STA PHARMACEUTICAL R&D CO., LTD. (CN) | 2024-07-04 | — | — | US | disclosed |
| US-20240199655-A1 | Immunoproteasome Inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2024-06-20 | — | — | US | disclosed |
| WO-2024112692-A1 | CASITAS B-LINEAGE LYMPHOMA PROTOONCOGENE B (CBL-B) DEGRADING COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. (US) | 2024-05-30 | — | — | WO | disclosed |
| CN-118005640-A | GCN2 inhibitors and uses thereof | 默克专利股份有限公司 | 2024-05-10 | — | — | CN | disclosed |
| US-11970498-B2 | CDK2 inhibitors | BLUEPRINT MEDICINES CORPORATION (US) | 2024-04-30 | — | — | US | disclosed |
| CN-112292129-B | Novel compounds and pharmaceutical compositions thereof for the treatment of diseases | 加拉帕戈斯股份有限公司 | 2024-04-19 | — | — | CN | disclosed |
| WO-2024077244-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISORDERS | HOTSPOT THERAPEUTICS, INC. (US) | 2024-04-11 | — | — | WO | disclosed |
| CN-114585628-B | Modulators of cystic fibrosis transmembrane conductance regulator | 弗特克斯药品有限公司 | 2024-03-26 | — | — | CN | disclosed |
| US-5763436-A | ANTICOAGULANTS | HOFFMANN-LA ROCHE INC. (US) | 1998-06-09 | — | — | US | disclosed |
| US-5763604-A | ANTICOAGULANTS | HOFFMANN-LA ROCHE INC. (US) | 1998-06-09 | — | — | US | disclosed |
| US-5677448-A | CHEMICAL INTERMEDIATES FOR MAKING ANTAGONIST OF THROMBIN, TREATING THROMBOSIS, STROKE, INFLAMMATION, ARTERIOSCLEROSIS, CARDIOVASCULAR DISORDERS | HOFFMANN-LA ROCHE INC. (US) | 1997-10-14 | — | — | US | disclosed |
| US-5595999-A | ANTICOAGULANTS | HOFFMANN-LA ROCHE INC. (US) | 1997-01-21 | — | — | US | disclosed |
| US-5583133-A | ANTICOAGULANTS | HOFFMANN-LA ROCHE INC. (US) | 1996-12-10 | — | — | US | disclosed |
| US-5578594-A | ANTICOAGULANTS | HOFFMANN-LA ROCHE INC. (US) | 1996-11-26 | — | — | US | disclosed |
| US-5532232-A | INHIBIT THROMBIN INDUCED PLATELET AGGREGATION; FIBRINOGEN ANTICOAGULANTS IN BLOOD | HOFFMANN-LA ROCHE INC. (US) | 1996-07-02 | — | — | US | disclosed |
| US-5405854-A | Anticoagulants | HOFFMANN-LA ROCHE INC. (US) | 1995-04-11 | — | — | US | disclosed |
| US-5393760-A | Cardiovascular disorders, antitumor agents | HOFFMANN-LA ROCHE INC. (US) | 1995-02-28 | — | — | US | disclosed |
| US-5260307-A | Inhibit thrombin-induced platlet aggregation and clotting of fibrogen in plasma | HOFMANN-LA ROCHE INC. (US) | 1993-11-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240199655-A1 | Immunoproteasome Inhibitors | PSMC2, PSMB7, PSMB2 | EPHX2 2767/4885RAB9A 1412/4885NPC1 743/4885 |
| US-11970498-B2 | CDK2 inhibitors | CDK2, CDK20, CDK2AP1 | EPHX2 4218/4885RAB9A 1585/4885NPC1 3514/4885 |
| US-20240217961-A1 | (S)-Mepazine Salt Forms, Process of Preparing, and Formulations Thereof | MEP1A, MEP1B, IL5 | EPHX2 801/4885RAB9A 2663/4885NPC1 1997/4885 |
| US-20240238423-A9 | TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-XL DEGRADERS | BCL2A1, BCL2L1, BCL3 | EPHX2 173/4885RAB9A 883/4885NPC1 2884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.